Literature DB >> 9121746

Allograft conjunctival transplantation for bilateral ocular surface disorders.

S Kwitko1, D Marinho, S Barcaro, F Bocaccio, S Rymer, S Fernandes, J Neumann.   

Abstract

PURPOSE: The purpose of this study is to evaluate the efficacy of allogenic conjunctival transplantation in bilateral surface disorders and to correlate with human leukocyte antigen (HLA) typing and cross-matching.
METHODS: A prospective study of allogenic conjunctival transplantation was undertaken in 12 eyes of 10 patients with bilateral surface disorders. Five eyes had Stevens-Johnson syndrome, three had Lyell syndrome, three had bilateral alkali burns, and one had a bilateral thermal burn. Human leukocyte antigen typing and cross-matching were retrospectively performed in eight patients and their respective donors. Stabilization of corneal epithelia, visual acuity, and rejection episodes were examined after the procedure.
RESULTS: Eleven (91.6%) of 12 eyes had improved visual acuity, corneal transparency and surface lubrication, stabilization of corneal epithelia, and decreased corneal neovascularization and photophobia after an average follow-up of 17.2 months. Three patients (25%) had rejection episodes, with no disturbance in corneal surface in two. Two of these three patients had 100% incompatible HLA donor-recipient pairs; HLA of the third patient was not available. Patients with favorable evolution were either HLA identical or haplo-identical (50% identity) with their donors. Donor eyes did not present any epithelial problems during the follow-up period.
CONCLUSIONS: Human leukocyte antigen-matched allogenic conjunctival transplantation proved to be an adequate method of treating severe bilateral surface disorders, with minimal complications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9121746     DOI: 10.1016/s0161-6420(95)30918-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  Long term results after autologous nasal mucosal transplantation in severe mucus deficiency syndromes.

Authors:  H Wenkel; V Rummelt; G O Naumann
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

2.  Limbal stem cell disease: Treatment and advances in technology.

Authors:  Hall F Chew
Journal:  Saudi J Ophthalmol       Date:  2011-05-24

Review 3.  Clinical correlates of common corneal neovascular diseases: a literature review.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Hamdy Salem; Ahmed E Elkhanany; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

4.  Allo-limbal transplantation in patients with limbal stem cell deficiency.

Authors:  H S Dua; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

5.  Epithelial transplantation for the management of severe ocular surface disease.

Authors:  E J Holland
Journal:  Trans Am Ophthalmol Soc       Date:  1996

6.  The long-term safety of donor eye for 180 degrees limbal transplantation.

Authors:  Eui Seok Han; Won Ryang Wee; Jin Hak Lee; Mee Kum Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-22       Impact factor: 3.117

7.  Allogenic cultivated limbal stem cell transplantation versus cadaveric keratolimbal allograft in ocular surface disorder: 1-year outcome.

Authors:  Jitendra Kumar Singh Parihar; Avinash Singh Parihar; Vaibhav Kumar Jain; Jaya Kaushik; Pramod Nath
Journal:  Int Ophthalmol       Date:  2016-12-26       Impact factor: 2.031

8.  Limbal stem cell transplantation: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2008-10-01

9.  Management of severe ocular burns with symblepharon.

Authors:  Weiyun Shi; Ting Wang; Hua Gao; Lixin Xie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-03       Impact factor: 3.117

10.  Short-term Efficacy of Topical Immunosuppressive Agents on the Survival of Cultivated Allo-Conjunctival Equivalents.

Authors:  Young Joo Shin; Mee Kum Kim; Joo Youn Oh; Won Ryang Wee; Jin Hak Lee; Jung Hwa Ko; Hyun Ju Lee; Jae Lim Lee; Byung Moo Min; Young Suk Sohn
Journal:  Korean J Ophthalmol       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.